Thyroid-specific changes following treatment with biological therapies in patients with rheumatic diseases

Endocrine

Volumn 50, Issue 1, 2015, Pages 146-153

  Kaklamanos, Michail ^a   Thomas, Dimitrios ^a   Pikazis, Dimitrios ^a   Kaltsas, Gregory ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Biological therapies; Rheumatic diseases; Thyroid autoimmunity

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; RITUXIMAB; THYROGLOBULIN ANTIBODY; THYROID ANTIBODY; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; ANTIRHEUMATIC AGENT; AUTOANTIBODY; THYROID HORMONE;

ADULT; ANALYTICAL PARAMETERS; ANTIBODY TITER; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; AUTOIMMUNITY; BIOLOGICAL THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; FEMALE; GRAY SCALE ECHOGRAPHY; HUMAN; LEFT INFERIOR THYROID ARTERY PEAK SYSTOLIC VELOCITY; LEFT THYROID LOBE VASCULARITY INDEX; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THYROID DISEASE; THYROID ECHOGENICITY; THYROID FUNCTION; THYROID WEIGHT; ADVERSE EFFECTS; AGED; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; ECHOGRAPHY; RHEUMATIC DISEASES; THYROID GLAND; VASCULARIZATION;

ADULT; AGED; ANTIRHEUMATIC AGENTS; AUTOANTIBODIES; BIOLOGICAL THERAPY; FEMALE; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; RHEUMATIC DISEASES; RITUXIMAB; THYROID GLAND; THYROID HORMONES; THYROIDITIS, AUTOIMMUNE;

EID: 84940437616     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-015-0551-8     Document Type: Article

References (35)

1. K.G. Saag, G.G. Teng, N.M. Patkar, J. Anuntiyo, C. Finney, J.R. Curtis et al., American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 59, 762–784 (2008)
2. D. El Fassi, C.H. Nielsen, H.C. Hasselbalch, L. Hegedus et al., The rationale for B lymphocyte depletion in Graves’ disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur. J. Endocrinol. 154, 623–632 (2006)
3. W.J. Sandborn, S.B. Hanauer, Infliximab in the treatment of Crohn’s disease: a user’s guide for clinicians. Am. J. Gastroenterol. 97, 2962–2972 (2002)
4. M.P. Vanderpump, W.M. Tunbridge, J.M. French, D. Appleton, D. Bates, F. Clark et al., The incidence of thyroid disorders in the community. A twenty year follow-up of the Whickham survey. Clin. Endocrinol. 43, 55–68 (1995)
5. R.D. Utiger, The pathogenesis of autoimmune thyroid disease. N. Engl. J. Med. 325, 278–279 (1991)
6. F. D´Arbonneau, S. Ansart, R. Le Berre, M. Dueymes, P. Youinou, Y.L. Pennec, Thyroid dysfunction in primary Sjogren’s syndrome: a long-term follow-up study. Arthritis Rheum. 49, 804–809 (2003)
7. J.B. Shiroky, M. Cohen, M.L. Ballachey, C. Neville, Thyroid dysfunction in rheumatoid arthritis: a controlled prospective survey. Ann. Rheum. Dis. 52, 454–456 (1993)
8. J.R. Garber, R.H. Cobin, H. Gharib, J.V. Hennessey, I. Klein, J.I. Mechanick et al., Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr. Pract. 18, 988–1028 (2012)
9. R. Gutekunst, W. Hafermann, T. Mansky, P.C. Scriba, Ultrasonography related to clinical and laboratory findings in lymphocytic thyroiditis. Acta Endocrinol. 121, 129–135 (1989)
10. W. Raber, A. Gessl, P. Nowotny, H. Vierhapper, Thyroid ultrasound versus antithyroid peroxidase antibody determination: a cohort study of four hundred fifty-one subjects. Thyroid 12, 725–731 (2002)
11. O.M. Pedersen, N.P. Aardal, T.B. Larssen, J.E. Varhaug, O. Myking, H. Vik-Mo, The value of ultrasonography in predicting autoimmune thyroid disease. Thyroid 10, 251–259 (2000)
12. I. Banaka, G. Kaltsas, S. Antoniou, G. Kanakis, A. Zilos, C. Baltas et al., Prognostic value of vascularity index for the diagnosis of autoimmune thyroid disease. JBR-BTR 94, 185–190 (2011)
13. I. Banaka, D. Thomas, G. Kaltsas, Value of the left inferior thyroid artery peak systolic velocity in diagnosing autoimmune thyroid disease. J. Ultrasound Med. 32, 1969–1978 (2013)
14. J.C. Mandac, S. Chaudhry, K.E. Sherman, Y. Tomer, The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology 43, 661–672 (2006)
15. A.J. Coles, M. Wing, S. Smith, F. Coraddu, S. Greer, C. Taylor, Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354, 1691–1695 (1995)
16. H.G. Raterman, A. Jamnitski, W.F. Lems, A.E. Voskuyl, B.A. Dijkmans, W.H. Bos, Improvement of thyroid function in hypothyroid patients with rheumatoid arthritis after 6 months of adalimumab treatment: a pilot study. J. Rheumatol. 38, 247–251 (2011)
17. C. Eriksson, S. Engstrand, K.G. Sundqvist, S. Rantapaa-Dahlqvist, Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFα. Ann. Rheum. Dis. 64, 403–407 (2005)
18. M. Kaklamanos, D. Thomas, D. Pikazis, S. Christaki, G. Kaltsas, The effect of rituximab in thyroid function and autoimmunity. Thyroid 23, 1044–1045 (2013)
19. F.C. Arnett, S.M. Edworthy, D.A. Bloch, D.J. McShane, J.F. Fries, N.S. Cooper et al., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31, 315–324 (1988)
20. E.M. Tan, A.S. Cohen, J.F. Fries, A.T. Masi, D.J. McShane, N.F. Rothfield et al., The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25, 1271–1277 (1982)
21. C. Vitali, S. Bombardieri, R. Jonsson, H.M. Moutsopoulos, E.L. Alexander, S.E. Carsons et al., European Study Group on Classification Criteria for Sjogren’s Syndrome: classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum. Dis. 61, 554–558 (2002)
22. Y. Murakami, J. Takamatsu, S. Sakane, K. Kuma, N. Ohsawa, Changes in thyroid volume in response to radioactive iodine for Graves’ hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome. J. Clin. Endocrinol. Metab. 81, 3257–3260 (1996)
23. L. Wartofsky, K.D. Burman, Alterations in thyroid function in patients with systemic illness: the « Euthyroid Sick Syndrome». Endocr. Rev. 3, 164–217 (1982)
24. J. Levy, E.V. Barnett, N.S. MacDonald, J.R. Klinenberg, Altered immunoglobulin metabolism in systemic lupus erythematosus and rheumatoid arthritis. J. Clin. Invest. 49, 708–715 (1970)
25. L.D. Xie, Y. Gao, M.R. Li, G.Z. Lu, X.H. Guo, Distribution of immunoglobulin G subclasses of anti-thyroid peroxidase antibody in sera from patients with Hashomoto’s thyroiditis with different thyroid functional status. Clin. Exp. Immunol. 154, 172–176 (2008)
26. R. Jansson, P. Thompson, F. Clark, S. McLachlan, Association between thyroid microsomal antibodies of subclass IgG-1 and hypothyroidism in autoimmune postpartum thyroiditis. Clin. Exp. Immunol. 63, 80–86 (1986)
27. M. Salvi, G. Vannucchi, I. Campi, N. Currò, D. Dazzi, S. Simonetta, Treatment of Grave’s disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur. J. Endocrinol. 156, 33–40 (2007)
28. D. El Fassi, C. Nielsen, S. Bonnema, H. Hasselbalch, L. Hegedus, B lymphocyte depletion with the monoclonal antibody Rituximab in Grave’s disease: a controlled pilot study. J. Clin. Endocrinol. Metab. 92, 1769–1772 (2007)
29. Y. Nagayama, H. Mizuguchi, T. Hayakawa, M. Niwa, S.M. McLachlan, B. Rapoport et al., Prevention of autoantibody-mediated Graves’-like hyperthyroidism in mice with IL-4, a Th2 cytokine. J. Immunol. 170, 3522–3527 (2003)
30. A.P. Weetman, Autoimmune thyroid disease: propagation and progression. Eur. J. Endocrinol. 148, 1–9 (2003)
31. D. Kurosaka, K. Hirai, M. Nishioka, Y. Miyamoto, K. Yoshida, K. Noda et al., Clinical significance of serum levels of vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in patients with rheumatoid arthritis. J. Rheumatol. 37, 1121–1128 (2010)
32. E.M. Paleolog, Angiogenesis in rheumatoid arthritis. Arthritis Res. 4, 81–90 (2002)
33. K. Sato, K. Yamazaki, K. Shizume, Y. Kanaji, T. Obara, K. Ohsumi et al., Stimulation by thyroid-stimulating hormone and Grave’s immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo. J. Clin. Invest. 96, 1295–1302 (1995)
34. M. Iitaka, S. Miura, K. Yamanaka, S. Kawasaki, S. Kitahama, Y. Kawakami et al., Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Grave’s disease and Hashimotos’ thyroiditis. J. Clin. Endocrinol. Metab. 83, 3908–3912 (1998)
35. A. Hauschild, H. Gogas, A. Tarhini, M.R. Middleton, A. Testori, B. Dreno et al., Practical guidelines for the management of interferon-α-2b side effects in patients receiving adjuvant treatment for melanoma. Cancer 112, 982–994 (2008)